Oct 2026· Reviews in cardiovascular medicine· Vol 27· 0 citations· 68 references
Medicine
TL;DR
Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting.
Abstract
Pure native aortic regurgitation (AR) remains a challenging and frequently undertreated valvular disease, associated with substantial morbidity and mortality. Surgical aortic valve repair or replacement remains the standard of care; however, many patients are older, frail, or at prohibitive surgical risk, creating an unmet need for less invasive therapeutic options. In this context, transcatheter aortic valve implantation (TAVI) has progressively emerged as a potential alternative. However, the application of TAVI in AR has historically been limited by the absence of annular and leaflet calcification, the presence of large and often noncircular annuli, and the resulting risks of transcatheter valve embolization or migration, residual paravalvular regurgitation, and conduction disturbances. This review summarizes contemporary evidence on TAVI for pure native AR, spanning early off-label experience with first-generation self-expanding and balloon-expandable valves to newer-generation platforms and dedicated devices. Recent observational studies and multicenter registries have shown meaningful improvements in procedural success, lower rates of residual AR and second valve implantation, and acceptable short- and mid-term mortality with contemporary off-label devices. Dedicated systems, including JenaValve Trilogy, J-Valve, and others, have further enhanced anchoring and sealing performance, achieving markedly lower rates of valve migration and significant residual regurgitation. Nonetheless, permanent pacemaker implantation remains a major limitation for several platforms. In parallel, the AURORA trial introduced an anatomy-guided strategy based on multidetector computed tomography classification and dual anchoring theory, suggesting that careful anatomical selection and optimized implantation planning may improve outcomes even with non-dedicated devices. Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting. Future progress will likely depend on further refinement of dedicated devices, reduction of conduction-related complications, and broader integration of patient-specific anatomical and biomechanical assessment to optimize device selection and implantation strategy.
Aortic stenosis is among the most common valvular heart diseases and, if untreated, can lead to
reduced quality of life and potential heart failure. Surgical Aortic Valve Replacement (SAVR) has long
been recognized as the standard treatment for severe aortic stenosis, while Transcatheter Aortic Valve
Replacement (TAVR)...
Dev Shah· American Journal of Student...· 0 citations
Transcatheter aortic valve replacement (TAVR) has transformed the treatment of severe aortic stenosis across all surgical risk profiles. However, as TAVR expands into younger, lower-risk populations with longer life expectancies, the management of late bioprosthetic failure has emerged as a critical clinical challenge....
Berk İnan, F. Iqbal, M. Tagliafierro et al.· Cardiology in Review· 0 citations
BACKGROUND
Until recently, no standard of care has been established for patients with symptomatic native aortic regurgitation (AR) who are unsuitable for surgery. Transcatheter aortic valve implantation (TAVI) has been explored in this setting using off-label, non-dedicated valves originally designed for aortic stenosi...
A. Messori, R. Brunoro, M. Rivano· Cardiovascular Revasculariza...· 0 citations
TAVI is feasible in selected patients with BAV stenosis, pure native AR, and small aortic annuli, but the evidentiary strength and optimal procedural strategy differ substantially across these anatomies.
D. Brie, Cristian Mornoș, Roxana Popescu et al.· Journal of Clinical Medicine· 0 citations
Aims Following the recent first-in-human experience of Valve in Mechanical Valve (ViMech), interest has emerged in understanding how frequently such an approach might be required in clinical practice. We performed an exploratory meta-analysis to characterize the long-term burden of valve-related complications and reint...
J. Ruiz-Ruiz, Akash Jain, M. García-Gómez et al.· Frontiers in Cardiovascular...· 0 citations
BACKGROUND
Transcatheter aortic valve replacement (TAVR) is well established for aortic stenosis, while its application for isolated native aortic regurgitation (AR) was previously off label and technically challenging. Comparative data between TAVR and surgical aortic valve replacement (SAVR) are limited.
OBJECTIVES...
Yukari Kobayashi, A. Kodesh, Maria C. Alu et al.· JACC: Cardiovascular Interve...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.